Share Price and Basic Stock Data
Last Updated: December 26, 2025, 10:45 pm
| PEG Ratio | -3.69 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aspira Pathlab & Diagnostics Ltd operates within the Hospitals & Medical Services industry, focusing on diagnostic services. The company’s share price stood at ₹63.4, and its market capitalization was ₹65.3 Cr. Over the past year, Aspira reported fluctuating revenue figures, with sales reaching ₹3.71 Cr in September 2022, peaking at ₹4.64 Cr in June 2024 before hitting ₹5.25 Cr in June 2025. However, there were notable declines, particularly in the March 2023 quarter, where sales fell to ₹3.41 Cr, and a significant drop to ₹2.60 Cr in June 2023. Annual sales figures also displayed volatility, with a total of ₹14.46 Cr for FY 2023, down from ₹19.54 Cr in FY 2022. The trailing twelve months (TTM) sales stood at ₹24.53 Cr, indicating a recovery trend as the company gears up for improved performance in subsequent quarters. This pattern suggests that while the company has faced challenges, it is working towards regaining its footing in the competitive diagnostics market.
Profitability and Efficiency Metrics
Aspira’s profitability remained under pressure, particularly evident in its operating profit margins (OPM), which recorded a negative OPM of -12.31% in June 2023 and -10.84% in September 2023. However, there is a notable recovery trajectory, with the OPM rising to 27.07% by September 2025. The company’s net profit for FY 2023 was reported at ₹0.02 Cr, reflecting a challenging year, although it rebounded to ₹2.07 Cr in FY 2025. The interest coverage ratio (ICR) demonstrated strength, standing at 11.27x, highlighting its ability to meet interest obligations comfortably. Return on equity (ROE) was impressive at 33.6%, indicating effective management of shareholder funds. Yet, the return on capital employed (ROCE) was lower at 17.4%, suggesting room for improvement in utilizing capital for growth. Overall, while profitability indicators have shown volatility, the recent uptick in operating margins and net profit showcases potential for future stability.
Balance Sheet Strength and Financial Ratios
Aspira’s balance sheet reflects a cautious financial posture, with total borrowings recorded at ₹3.13 Cr and reserves standing at ₹4.13 Cr. The company’s current ratio was healthy at 2.26x, indicating it can cover its short-term liabilities comfortably. The price-to-book value (P/BV) ratio was reported at 12.12x, suggesting that the market values the company significantly higher than its book value, which stood at ₹7.03 per share as of FY 2025. The enterprise value (EV) was ₹86.79 Cr, translating to an EV/EBITDA of 22.18x, highlighting market confidence despite the operational challenges. The cash conversion cycle was relatively efficient at 16.30 days, reflecting effective management of working capital. However, the negative reserves in recent years point to historical financial challenges that the company has faced, necessitating close monitoring of its capital management strategies.
Shareholding Pattern and Investor Confidence
The shareholding composition of Aspira Pathlab indicates a strong public interest, with public shareholders holding 81.61% of the equity as of September 2025. Promoter holding has seen a gradual decline from 19.48% in December 2022 to 18.39% in March 2025. The number of shareholders has increased from 1,300 in December 2022 to 1,755 by September 2025, suggesting growing investor confidence and interest in the company despite its recent operational struggles. The absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may imply a cautious stance from larger institutional players, possibly due to the company’s historical performance volatility. This high public ownership could provide stability, as retail investors often have a long-term perspective. However, the consistent decline in promoter shareholding could raise concerns about insider confidence in the company’s future.
Outlook, Risks, and Final Insight
The outlook for Aspira Pathlab remains cautiously optimistic, given the recent improvements in profitability and operational efficiency. Key strengths include a strong interest coverage ratio and a healthy current ratio, which support the company’s ability to navigate financial obligations. However, risks persist, including dependence on diagnostic services in a competitive market and fluctuating sales trends that may impact revenue stability. The company must focus on enhancing operational efficiency and maintaining a positive trajectory in profitability metrics to bolster investor confidence. Should Aspira continue to improve its margins and manage its capital effectively, it could position itself favorably in the diagnostics sector. Conversely, any significant downturns in sales or persistent operational challenges could hinder its recovery and growth prospects.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 44.8 Cr. | 134 | 187/120 | 9.14 | 117 | 2.62 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 24.5 Cr. | 23.4 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 7.90 Cr. | 7.64 | 20.8/7.08 | 87.8 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 112 Cr. | 59.9 | 98.7/55.2 | 24.8 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.8 Cr. | 3.67 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,411.86 Cr | 696.56 | 92.72 | 93.18 | 0.33% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3.71 | 4.37 | 3.41 | 2.60 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 | 8.09 |
| Expenses | 3.25 | 3.56 | 3.26 | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 | 5.90 |
| Operating Profit | 0.46 | 0.81 | 0.15 | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 | 2.19 |
| OPM % | 12.40% | 18.54% | 4.40% | -12.31% | -10.84% | -10.69% | -3.40% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% | 27.07% |
| Other Income | 0.07 | 0.12 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 | 0.14 |
| Interest | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 |
| Depreciation | 0.40 | 0.39 | 0.38 | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 | 0.40 |
| Profit before tax | 0.02 | 0.44 | -0.26 | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 | 1.83 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.02 | 0.44 | -0.26 | -0.72 | -0.71 | -0.74 | -0.50 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 | 1.84 |
| EPS in Rs | 0.02 | 0.43 | -0.25 | -0.70 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 | 1.79 |
Last Updated: December 28, 2025, 12:16 am
Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8.09 Cr.. The value appears strong and on an upward trend. It has increased from 5.25 Cr. (Jun 2025) to 8.09 Cr., marking an increase of 2.84 Cr..
- For Expenses, as of Sep 2025, the value is 5.90 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.44 Cr. (Jun 2025) to 5.90 Cr., marking an increase of 1.46 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.19 Cr.. The value appears strong and on an upward trend. It has increased from 0.81 Cr. (Jun 2025) to 2.19 Cr., marking an increase of 1.38 Cr..
- For OPM %, as of Sep 2025, the value is 27.07%. The value appears strong and on an upward trend. It has increased from 15.43% (Jun 2025) to 27.07%, marking an increase of 11.64%.
- For Other Income, as of Sep 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Jun 2025) to 0.14 Cr., marking an increase of 0.03 Cr..
- For Interest, as of Sep 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Jun 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Sep 2025, the value is 0.40 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.37 Cr. (Jun 2025) to 0.40 Cr., marking an increase of 0.03 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.83 Cr.. The value appears strong and on an upward trend. It has increased from 0.46 Cr. (Jun 2025) to 1.83 Cr., marking an increase of 1.37 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is 1.84 Cr.. The value appears strong and on an upward trend. It has increased from 0.47 Cr. (Jun 2025) to 1.84 Cr., marking an increase of 1.37 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.79. The value appears strong and on an upward trend. It has increased from 0.46 (Jun 2025) to 1.79, marking an increase of 1.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:09 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | 24.53 |
| Expenses | 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 19.72 |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.56 | 4.81 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 19.61% | |||
| Other Income | 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.36 | 0.47 |
| Interest | 0.00 | 0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.37 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.53 |
| Profit before tax | 0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 3.38 |
| Tax % | 57.14% | 25.00% | 0.00% | 0.00% | 0.00% | 0.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 3.41 |
| EPS in Rs | 0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 3.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | -9166.67% | -105.15% | 7.17% | 18.15% | 132.55% | 223.19% | -102.02% | -2866.67% | 177.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -9216.67% | 9061.52% | 112.32% | 10.98% | 114.40% | 90.64% | -325.21% | -2764.65% | 3044.19% |
Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 13% |
| 1 Year: | 99% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:26 am
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 0.19 | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | -3.01 | 4.13 |
| Borrowings | 0.00 | 0.00 | 2.62 | 7.29 | 11.36 | 12.52 | 13.80 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 | 3.13 |
| Other Liabilities | 0.03 | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 | 2.61 |
| Total Liabilities | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
| Fixed Assets | 0.00 | 0.00 | 0.04 | 7.79 | 7.91 | 8.90 | 8.70 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | 6.71 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.00 |
| Other Assets | 0.62 | 3.82 | 6.25 | 6.82 | 4.62 | 5.90 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 | 13.45 |
| Total Assets | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
Below is a detailed analysis of the balance sheet data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.29 Cr..
- For Reserves, as of Sep 2025, the value is 4.13 Cr.. The value appears strong and on an upward trend. It has increased from -3.01 Cr. (Mar 2025) to 4.13 Cr., marking an increase of 7.14 Cr..
- For Borrowings, as of Sep 2025, the value is 3.13 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.13 Cr. (Mar 2025) to 3.13 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.11 Cr. (Mar 2025) to 2.61 Cr., marking an increase of 0.50 Cr..
- For Total Liabilities, as of Sep 2025, the value is 20.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
- For Fixed Assets, as of Sep 2025, the value is 6.71 Cr.. The value appears strong and on an upward trend. It has increased from 6.53 Cr. (Mar 2025) to 6.71 Cr., marking an increase of 0.18 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.13 Cr..
- For Other Assets, as of Sep 2025, the value is 13.45 Cr.. The value appears strong and on an upward trend. It has increased from 10.86 Cr. (Mar 2025) to 13.45 Cr., marking an increase of 2.59 Cr..
- For Total Assets, as of Sep 2025, the value is 20.16 Cr.. The value appears strong and on an upward trend. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
Notably, the Reserves (4.13 Cr.) exceed the Borrowings (3.13 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.02 | -0.14 | -2.85 | -9.87 | -15.24 | -15.76 | -15.63 | -3.49 | -2.47 | -6.64 | -8.89 | -4.57 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -2,199.61 | -5.86 | -96.03 | -127.01 | 16.32 | 69.30 | 48.72 | 25.16 | 14.10 | |||
| ROCE % | 0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.97 | -2.60 |
| Diluted EPS (Rs.) | 1.97 | -2.60 |
| Cash EPS (Rs.) | 3.46 | -1.10 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.03 | 5.07 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.03 | 5.07 |
| Revenue From Operations / Share (Rs.) | 21.37 | 12.83 |
| PBDIT / Share (Rs.) | 3.80 | -0.74 |
| PBIT / Share (Rs.) | 2.35 | -2.24 |
| PBT / Share (Rs.) | 2.01 | -2.60 |
| Net Profit / Share (Rs.) | 2.01 | -2.60 |
| NP After MI And SOA / Share (Rs.) | 1.97 | -2.60 |
| PBDIT Margin (%) | 17.79 | -5.79 |
| PBIT Margin (%) | 11.00 | -17.45 |
| PBT Margin (%) | 9.42 | -20.23 |
| Net Profit Margin (%) | 9.42 | -20.23 |
| NP After MI And SOA Margin (%) | 9.19 | -20.23 |
| Return on Networth / Equity (%) | 27.94 | -51.25 |
| Return on Capital Employeed (%) | 16.03 | -18.23 |
| Return On Assets (%) | 11.58 | -18.16 |
| Asset Turnover Ratio (%) | 1.37 | 0.00 |
| Current Ratio (X) | 2.26 | 2.10 |
| Quick Ratio (X) | 2.05 | 1.89 |
| Inventory Turnover Ratio (X) | 45.90 | 0.00 |
| Interest Coverage Ratio (X) | 11.27 | -2.08 |
| Interest Coverage Ratio (Post Tax) (X) | 6.97 | -6.27 |
| Enterprise Value (Cr.) | 86.79 | 31.60 |
| EV / Net Operating Revenue (X) | 3.95 | 2.39 |
| EV / EBITDA (X) | 22.18 | -41.27 |
| MarketCap / Net Operating Revenue (X) | 3.99 | 2.42 |
| Price / BV (X) | 12.12 | 6.12 |
| Price / Net Operating Revenue (X) | 3.99 | 2.42 |
| EarningsYield | 0.02 | -0.08 |
After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. It has increased from -1.10 (Mar 24) to 3.46, marking an increase of 4.56.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 7.03. It has increased from 5.07 (Mar 24) to 7.03, marking an increase of 1.96.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 7.03. It has increased from 5.07 (Mar 24) to 7.03, marking an increase of 1.96.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. It has increased from 12.83 (Mar 24) to 21.37, marking an increase of 8.54.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. It has increased from -0.74 (Mar 24) to 3.80, marking an increase of 4.54.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. It has increased from -2.24 (Mar 24) to 2.35, marking an increase of 4.59.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from -2.60 (Mar 24) to 2.01, marking an increase of 4.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. It has increased from -2.60 (Mar 24) to 2.01, marking an increase of 4.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. It has increased from -2.60 (Mar 24) to 1.97, marking an increase of 4.57.
- For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. It has increased from -5.79 (Mar 24) to 17.79, marking an increase of 23.58.
- For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. It has increased from -17.45 (Mar 24) to 11.00, marking an increase of 28.45.
- For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. It has increased from -20.23 (Mar 24) to 9.42, marking an increase of 29.65.
- For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. It has increased from -20.23 (Mar 24) to 9.42, marking an increase of 29.65.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. It has increased from -20.23 (Mar 24) to 9.19, marking an increase of 29.42.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.94. This value is within the healthy range. It has increased from -51.25 (Mar 24) to 27.94, marking an increase of 79.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. It has increased from -18.23 (Mar 24) to 16.03, marking an increase of 34.26.
- For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. It has increased from -18.16 (Mar 24) to 11.58, marking an increase of 29.74.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.37. It has increased from 0.00 (Mar 24) to 1.37, marking an increase of 1.37.
- For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.26, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. It has increased from 1.89 (Mar 24) to 2.05, marking an increase of 0.16.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 45.90. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 45.90, marking an increase of 45.90.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from -2.08 (Mar 24) to 11.27, marking an increase of 13.35.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. It has increased from -6.27 (Mar 24) to 6.97, marking an increase of 13.24.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. It has increased from 31.60 (Mar 24) to 86.79, marking an increase of 55.19.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. It has increased from 2.39 (Mar 24) to 3.95, marking an increase of 1.56.
- For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. It has increased from -41.27 (Mar 24) to 22.18, marking an increase of 63.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.99, marking an increase of 1.57.
- For Price / BV (X), as of Mar 25, the value is 12.12. This value exceeds the healthy maximum of 3. It has increased from 6.12 (Mar 24) to 12.12, marking an increase of 6.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.99, marking an increase of 1.57.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from -0.08 (Mar 24) to 0.02, marking an increase of 0.10.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
- Net Profit Margin: 9.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.03% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.94% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.1 (Industry average Stock P/E: 92.72)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.42%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086 | info@aspiradiagnostics.com http://www.aspiradiagnostics.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Haseeb A Drabu | Chairman & Ind.Director |
| Dr. Pankaj J Shah | Managing Director & CEO |
| Mr. Nikunj V Mange | Executive Director |
| Mrs. Mangala R Prabhu | Independent Director |
| Dr. Manas R Mengar | Independent Director |
FAQ
What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd's intrinsic value (as of 28 December 2025) is 73.31 which is 15.63% higher the current market price of 63.40, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 65.3 Cr. market cap, FY2025-2026 high/low of 107/50.5, reserves of ₹4.13 Cr, and liabilities of 20.16 Cr.
What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?
The Market Cap of Aspira Pathlab & Diagnostics Ltd is 65.3 Cr..
What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 28 December 2025?
The current stock price of Aspira Pathlab & Diagnostics Ltd as on 28 December 2025 is 63.4.
What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is 107/50.5.
What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?
The Stock P/E of Aspira Pathlab & Diagnostics Ltd is 19.1.
What is the Book Value of Aspira Pathlab & Diagnostics Ltd?
The Book Value of Aspira Pathlab & Diagnostics Ltd is 14.0.
What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?
The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.
What is the ROCE of Aspira Pathlab & Diagnostics Ltd?
The ROCE of Aspira Pathlab & Diagnostics Ltd is 17.4 %.
What is the ROE of Aspira Pathlab & Diagnostics Ltd?
The ROE of Aspira Pathlab & Diagnostics Ltd is 33.6 %.
What is the Face Value of Aspira Pathlab & Diagnostics Ltd?
The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.